Swisscanto Private Equity
VC Fund
Zürich, Switzerland
Swisscanto Private Equity is a VC fund in Zürich focused on Health Care and Biotechnology. We invest in growth companies in the "late-stage venture/growth capital" phase, focussed on the technology and healthtech sectors.
- Total investments:
- 35
- Last investment:
- Lead investor:
- 37%
- Fund size:
- $204M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Swisscanto Private Equity invests in
Stages Swisscanto Private Equity invests in
Countries Swisscanto Private Equity invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Series B
- $9.2M–$52M
- Series C
- $22M–$54M
- Venture - Series Unknown
- $20M–$47M
Investment Focus
Industry
- Health Care 4 (11%)
- Biotechnology 4 (11%)
- Manufacturing 4 (11%)
- Robotics 3 (9%)
- Health Diagnostics 3 (9%)
Stage
- Series B 12 (34%)
- Series C 3 (9%)
- Venture - Series Unknown 3 (9%)
- Series A 1 (3%)
- Series D 1 (3%)
Country
- Switzerland 12 (34%)
- Denmark 2 (6%)
- Germany 2 (6%)
- Belgium 1 (3%)
- Finland 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Robert Schier
Investment Director
|
Investment Director | Total investments: 11 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ecorobotix
|
ecoRobotix contributes to an agriculture that respects the environment, focusing on soil and hydrological resources conservation and using a minimum amount of energy. ecoRobotix aims to offer precise, safe, reliable and affordable robotic solutions that simplify farmers’ life to produce healthy food. In particular, its revolutionary solar-poweredweeding robot offers a more sustainable use of herbicides while reducing farmers costs. | $105.7M / Series D / Oct 13, 2025 | |
MedTrace Pharma
|
MedTrace develops a hardware platform (MT-100) that automates the production and injection of the gold standard tracer 15O-water into the patient. MedTrace also develops an analytical software platform to interpret the results from the PET scanner.By use of 15O-water, doctors will increase sensitivity in the analysis of the patient while at thesame time increasing patient throughput up to a factor of 4 compared to today's clinical workhorse. | $11.1M / Series F / May 12, 2025 | |
ANYbotics
|
ANYbotics is a manufacturer of four-legged robots intended for a variety of industrial uses. The company enhances safety and productivity in industrial operations through autonomous mobile robots capable of navigating complex environments. It provides solutions for robot applications with the most advanced mobility and autonomy requirements inchallenging terrain.ANYbotics was founded in 2016 and is headquartered in Zürich, Switzerland. | $60M / Series B / Dec 12, 2024 | |
Memo Therapeutics
|
Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations. | $22M / Series C / May 07, 2024 | |
|
Memo Therapeutics
|
Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations. | $22M / Series C / May 07, 2024 | |
NIL Technology ApS
|
NIL Technology ApS (NILT) takes optical applications to a new level of performance, efficiency, and compactness, by combining diffractive, refractive, and meta optics. As a result, NILT creates competitive advantages with flat optics in optical applications for 3D sensing, consumer electronics, machine vision, autonomous vehicles, and VR/MRdisplays. Products include optical elements and components, waveguides for AR/MR, and masters. | $31.2M / Venture - Series Unknown / May 07, 2024 | |
Fotokite
|
Fotokite is a team of autonomous vehicle and aerial robotics experts set out with a mission to help first responders save lives and preserve property. Our patented technology enables us to provide solutions that get installed in the top of fire trucks and public safety vehicles, so that when a firefighter shows up to their scene, they push a singlebutton, and their Fotokite system opens up, deploys itself, and flies up to 45 meters in height to provide the first responders with mission-critical information about their scene. From up there, we provide both thermal and regular video down to the ground to give teams visibility and elevated intelligence over their scene.The information delivered helps them size up and assess their incidents quickly and without drawing additional team resources like normal drones. We actively use a tether to provide power up the line and data down the line to deliver a fully autonomous, situational awareness system with 24-hour-plus flight times. The real benefit to the user is the fact that they gain this information without ever piloting the system- it’s as simple as it gets. They simply push “launch” on a tablet, set their altitude and camera angle, and the system takes care of the rest. Once up in the air, the system is also set up to live stream that aerial information to other teams on the same site, or back at the fire station to provide more eyes on the scene than were possible before. They use this information to gain perspective and context of their incident, and then deploy their resources in a more data-informed way. | $11M / Series B / Apr 11, 2024 | |
|
Memo Therapeutics
|
Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations. | $27.6M / Series C / Nov 02, 2023 | |
Nagi Bioscience
|
Nagi Bioscience aims to revolutionize the way toxic and/or beneficial effects of substances are tested today, by introducing the first “Organism-on-Chip” technology. | $14.5M / Series A / Sep 28, 2023 | |
|
MedTrace Pharma
|
MedTrace develops a hardware platform (MT-100) that automates the production and injection of the gold standard tracer 15O-water into the patient. MedTrace also develops an analytical software platform to interpret the results from the PET scanner.By use of 15O-water, doctors will increase sensitivity in the analysis of the patient while at thesame time increasing patient throughput up to a factor of 4 compared to today's clinical workhorse. | $19M / Sep 21, 2023 | |
| See all 35 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Swisscanto Private Equity invest in?
Swisscanto Private Equity invests primarily in Health Care, Biotechnology and Manufacturing startups, most often at Series B and Series C stage. Most of the 35 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Swisscanto Private Equity's check size?
Swisscanto Private Equity typically joins rounds of $9.2M–$52M at Series B, $22M–$54M at Series C and $20M–$47M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Swisscanto Private Equity participates in.
How do I contact Swisscanto Private Equity?
Public channels for Swisscanto Private Equity include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Swisscanto Private Equity?
The team at Swisscanto Private Equity includes Robert Schier (Investment Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
